Xencor, Inc. (NASDAQ:XNCR) CEO Sells $1,186,121.46 in Stock

Xencor, Inc. (NASDAQ:XNCR) CEO Bassil I. Dahiyat sold 49,278 shares of the firm’s stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $24.07, for a total transaction of $1,186,121.46. Following the sale, the chief executive officer now owns 352,615 shares in the company, valued at approximately $8,487,443.05. The trade was a 12.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Xencor Stock Down 2.9 %

XNCR stock opened at $25.30 on Wednesday. Xencor, Inc. has a twelve month low of $15.31 and a twelve month high of $26.84. The company has a market cap of $1.77 billion, a price-to-earnings ratio of -8.14 and a beta of 0.66. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average price of $21.57 and a two-hundred day moving average price of $20.39.

Xencor (NASDAQ:XNCR) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.98) by $0.27. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business had revenue of $10.70 million during the quarter, compared to analysts’ expectations of $14.59 million. During the same period last year, the business earned ($0.40) earnings per share. The firm’s revenue was down 81.9% on a year-over-year basis. Analysts anticipate that Xencor, Inc. will post -3.71 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

XNCR has been the subject of a number of research reports. BMO Capital Markets reiterated an “outperform” rating and set a $34.00 target price (up previously from $32.00) on shares of Xencor in a report on Friday, November 8th. Royal Bank of Canada increased their price objective on Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a report on Thursday, September 26th. JPMorgan Chase & Co. boosted their target price on Xencor from $27.00 to $28.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Finally, Wedbush reaffirmed an “outperform” rating and set a $38.00 price target on shares of Xencor in a research note on Thursday, November 7th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Xencor presently has an average rating of “Moderate Buy” and a consensus price target of $35.75.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of XNCR. Jacobs Levy Equity Management Inc. bought a new position in Xencor during the first quarter worth about $4,608,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Xencor by 9.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,819,656 shares of the biopharmaceutical company’s stock worth $84,530,000 after acquiring an additional 335,881 shares during the period. Panagora Asset Management Inc. raised its stake in Xencor by 9.4% in the 2nd quarter. Panagora Asset Management Inc. now owns 232,375 shares of the biopharmaceutical company’s stock valued at $4,399,000 after acquiring an additional 20,043 shares during the period. Primecap Management Co. CA lifted its holdings in Xencor by 0.3% during the 2nd quarter. Primecap Management Co. CA now owns 9,116,202 shares of the biopharmaceutical company’s stock valued at $172,570,000 after purchasing an additional 25,495 shares during the last quarter. Finally, AQR Capital Management LLC bought a new position in Xencor during the second quarter worth $753,000.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.